ArticleBreast cancer research and treatment2018
Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker.The British journal of radiology · 2021Pooled it
- The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.Breast cancer research and treatment · 2022Trial
- The relationship between background parenchymal enhancement, amount of fibroglandular tissue and synchronous contralateral breast cancer in preoperative magnetic resonance imaging of newly diagnosed breast cancer patients.BMC medical imaging · 2026Article
- Clinicopathological and imaging factors of surgical margin status and prognosis in breast-conserving therapy.Scientific reports · 2026Article
- Histologic correlates of background parenchymal uptake on molecular breast imaging.Breast cancer research : BCR · 2025Observational
- Multiparametric MRI Markers Associated with Breast Cancer Risk in Women with Dense Breasts.Cancers · 2025Article
- Breast MRI to Screen Women With Extremely Dense Breasts.Journal of magnetic resonance imaging : JMRI · 2025Review
- Background parenchymal enhancement of the contralateral breast on preoperative contrast-enhanced breast MRI as a potential predictive factor for disease-free survival in triple-negative breast cancer patients.Frontiers in oncology · 2025Article
- Are background breast parenchymal features on preoperative breast MRI associated with disease-free survival in patients with invasive breast cancer?La Radiologia medica · 2024Article
- Background parenchymal enhancement on contrast-enhanced mammography: associations with breast density and patient's characteristics.La Radiologia medica · 2024Article
- Quantitative evaluation of Kaiser score in diagnosing breast dynamic contrast-enhanced magnetic resonance imaging for patients with high-grade background parenchymal enhancement.Quantitative imaging in medicine and surgery · 2023Article
- Association of Breast Cancer Odds with Background Parenchymal Enhancement Quantified Using a Fully Automated Method at MRI: The IMAGINE Study.Radiology · 2023Article
- Beyond Breast Density: Risk Measures for Breast Cancer in Multiple Imaging Modalities.Radiology · 2023Review
- Ipsilateral Recurrence of DCIS in Relation to Radiomics Features on Contrast Enhanced Breast MRI.Tomography (Ann Arbor, Mich.) · 2022Article
- Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk.AJR. American journal of roentgenology · 2021Article
- High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.American journal of translational research · 2021Article
- The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI.Acta radiologica (Stockholm, Sweden : 1987) · 2020Article
- Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.Journal of breast imaging · 2020Article
- Review
- Background parenchymal enhancement on breast MRI: A comprehensive review.Journal of magnetic resonance imaging : JMRI · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeBreast fibroglandular tissue (FGT), as visualized on a mammogram (mammographic density, MD), is one of the strongest known risk factors for breast cancer. FGT is also visible on breast MRI, and increased background parenchymal enhancement (BPE) in the FGT has been identified as potentially a major breast cancer risk factor. The aim of this exploratory study was to examine the biologic basis of BPE.
methodsWe examined the unaffected contra-lateral breast of 80 breast cancer patients undergoing a prophylactic mastectomy before any treatment other than surgery of their breast cancer. BPE was classified on the BI-RADS scale (minimal/mild/moderate/marked). Slides were stained for microvessel density (MVD), CD34 (another measure of endothelial density), glandular tissue within the FGT and VEGF. Spearman correlations were used to evaluate the associations between BPE and these pathologic variables.
resultsIn pre-menopausal patients, BPE was highly correlated with MVD, CD34 and glandular concentration within the FGT, and the pathologic variables were themselves highly correlated. The expression of VEGF was effectively confined to terminal duct lobular unit (TDLU) epithelium. The same relationships of the four pathologic variables with BPE were seen in post-menopausal patients, but the relationships were much weaker and not statistically significant.
conclusionThe strong correlation of BPE and MVD together with the high correlation of MVD with glandular concentration seen in pre-menopausal patients indicates that increased breast cancer risk associated with BPE in pre-menopausal women is likely to result from its association with increased concentration of glandular tissue in the FGT. The effective confinement of VEGF expression to the TDLUs shows that the signal for MVD growth arises directly from the glandular tissue. Further studies are needed to understand the basis of BPE in post-menopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.